Phase I/II Study of Sacituzumab Govitecan and Berzosertib in Small Cell Lung Cancer
A Phase I/II trial is investigating the combination of sacituzumab govitecan and berzosertib in patients with small cell lung cancer and PARP inhibitor-resistant tumors.
Phase I
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase I/II trial of sacituzumab govitecan and berzosertib could significantly impact treatment options for small cell lung cancer and PARP inhibitor-resistant tumors, which currently have limited effective therapies. Success in this trial may reshape competitive dynamics and influence portfolio strategies for oncology-focused companies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety, as well as any announcements regarding further development or partnerships.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.